Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy

Journal of Clinical Oncology

Volumn 22, Issue 5, 2004, Pages 927-934

  Yeo, Winnie ^a   Chan, Paul K S ^a   Ho, Wing M ^a   Zee, Benny ^a   Lam, Kwok C ^a   Lei, Kenny I K ^a   Chan, Anthony T C ^a   Mok, Tony S K ^a   Lee, Jam J ^a   Leung, Thomas W T ^a   Zhong, Sheng ^a   Johnson, Philip J ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE;

ADULT; ARTICLE; CANCER; CHEMOTHERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INCIDENCE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROPHYLAXIS; STATISTICAL ANALYSIS; VIRUS REACTIVATION; AGE DISTRIBUTION; AGED; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; HETEROZYGOTE; ISOLATION AND PURIFICATION; METHODOLOGY; MIDDLE AGED; NEOPLASM; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PRIMARY PREVENTION; PROBABILITY; PROGNOSIS; RECURRENT DISEASE; REFERENCE VALUE; RISK ASSESSMENT; SEROLOGY; SEX RATIO; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGE DISTRIBUTION; AGED; CARRIER STATE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; INCIDENCE; LAMIVUDINE; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; PRIMARY PREVENTION; PROBABILITY; PROGNOSIS; RECURRENCE; REFERENCE VALUES; RISK ASSESSMENT; SEROLOGIC TESTS; SEX DISTRIBUTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 1542503712     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.05.161     Document Type: Article

References (33)

1. Lee WM: Hepatitis B virus infection. N Engl J Med 337:1733-1745, 1997
2. Lok ASF, Lai CL, Wu PC: Hepatitis B virus infection in Chinese families in Hong Kong. Am J Epidemiol 126:492-499, 1987
3. Galbraith RM, Eddleston AL, Williams R, et al: Fulminating hepatic failure in leukemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet 2:528-530, 1975
4. Thung SN, Gerber MA, Klion F, et al: Massive hepatic necrosis after chemotherapy withdrawal in a hepatitis B carrier. Arch Intern Med 145:1313-1314, 1985
5. Bird GL, Smith H, Portmann B, et al: Acute liver decompensation on withdrawal of cytotoxic and immunosuppressive therapy in hepatitis B carriers. Q J Med 73:895-902, 1989
6. Lok ASF, Liang RHS, Chiu EKW, et al: Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 100: 182-188, 1991
7. Soh LT, Ang PT, Sng I, et al: Fulminant hepatic failure in non- Hodgkin lymphoma patients treated with chemotherapy. Eur J Cancer 28A: 1338-1339, 1992
8. Nokamura Y, Motokura T, Fujita A, et al: Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987-1991. Cancer 782210-2215, 1996
9. Kumagai K, Takagi T, Nakamura S, et al: Hepatitis B virus carriers in the treatment of malignant lymphoma: An epidemiological study in Japan. Ann Oncol 8:107-109, 1997
10. Hoofnagle JH, Dusheiko GM, Schafer DF, et al: Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 96:447-4491, 1982
11. Alexopoulos CG, Vaslamatzis M, Hatzidimitriou G: Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours. Br J Cancer 81:69-74, 1999
12. Yeo W, Chan PKS, Zhong S, et al: Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factors. J Med Virol 62:299-307, 2000
13. Coleman MP, Esteve J, Damiecki P, Arslan A, Renard H: Trends in cancer incidence and mortality. International Agency for Research on Cancer, Oxford University Press Oxford, UK. 1993
14. Borg FT, Smorenburg S, De Man RA, et al: Recovery from life-threatening corticosteroid-unresponsive, chemotherapy-related reactivation of hepatitis B associated with lamivudine therapy. Dig Dis Sci 43:2267-2270, 1998
15. Clark FL, Drummond MW, Chambers S, et al: Successful treatment of lamivudine for fulminant hepatitis B infection following intensive therapy for high grade non-Hodgkin's lymphoma. Ann Oncol 9:385-387, 1998
16. Yeo W, Steinberg JL, Tam JS, et al: Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy. J Med Virol 59:263-269, 1999
17. Ahmed A, Keeffe EB: Lamivudine therapy in chemotherapy-induced reactivation of hepatitis B virus infection. Am J Gastroenterol 94:249-263, 1999
18. Cainelli F, Longhi MS, Concia E, et al: Failure of lamivudine therapy for chemotherapy-induced reactivation of hepatitis B. Am J Gastroenterol 96:1651-1652, 2001
19. Yeo W, Chan PKS, Chan HLY, et al: Hepatitis B virus reactivation during cytotoxic chemotherapy- enhanced viral replication precedes overt hepatitis. J Med Virol 65:473-477, 2001
20. Al-Taie OH, Mork H, Gassel AM, et al: Prevention of hepatitis B flare-up during chemotherapy using lamivudine: Case report and review of the literature. Ann Hematol 78:247-249, 1999
21. Silvestri F, Ermacora A, Sperotto A, et al: Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivation. Br J Haematol 108:394-396, 2000
22. Chan SW, McOmish F, Holmes EC, et al: Analysis of a new hepatitis C virus type and its phylogenetic relationship to existing variants. J Gen Virol 73:1131-1141, 1992
23. Hosmer DW, Lemeshow S: Applied Logistic Regression, Wiley, 1989
24. Persico M, De Marino F, Russo GD, et al: Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin lymphoma. Blood 99(2): 724-725, 2002
25. Lim LL, Wai CT, Lee YM, et al: Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients. Aliment Pharmacol Ther 16:1939-1944, 2002
26. Shibolet O, Ilan Y, Gillis S, et al: Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood 100:391-396, 2002
27. Rossi G, Pelizzari A, Motta M, et al: Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HBsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol 115(1):58-62, 2001
28. Lau GKK, He ML, Fong DYT, et al: Pre-emptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology 36:702-709, 2002
29. Ling R, Mutimer D, Ahmed N, et al: Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 24:711-713, 1996
30. Bartholomew MM, Jansen RW, Jeffers LJ, et al: Hepatitis B-virus resistant to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 349:20-22, 1997
31. Lai CL, Chien RN, Leung NW, et al: A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 339:61-68, 1998
32. Liaw YF: Management of YMDD mutation during lamivudine therapy in patients with chronic hepatitis B. J Gastroenterol Hepatol 17: S333-337, 2002
33. Liaw YF, Leung NWY, Chang TT, et al: Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 119:172-180, 2000